BN80915

diflomotecan · Ipsen

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BN80915, covering 2020-04-29 to 2020-04-29. Get the full timeline:

Most recent: Clinical Trial Update: Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) [Phase 2]

See pricing